Stromal Cell Signature Associated with Response to Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer

Maria Lucia Hirata Katayama, Rene Aloisio Costa Vieira, Victor Piana Andrade, Rosimeire Aparecida Roela, Luiz Guilherme Cernaglia Aureliano Lima, Ligia Maria Kerr, Adriano Polpo de Campos, Carlos Alberto de Braganca Pereira, Pedro Adolpho de Menezes Pacheco Serio, Giselly Encinas, Simone Maistro, Matheus de Almeida Leite Petroni, Maria Mitzi Brentani, Maria Aparecida Azevedo Koike Folgueira

Research output: Contribution to journalArticle

Abstract

Breast cancer stromal compartment, may influence responsiveness to chemotherapy. Our aim was to detect a stromal cell signature (using a direct approach of microdissected stromal cells) associated with response to neoadjuvant chemotherapy (neoCT) in locally advanced breast cancer (LABC). The tumor samples were collected from 44 patients with LABC (29 estrogen receptor (ER) positive and 15 ER negative) before the start of any treatment. Neoadjuvant chemotherapy consisted of doxorubicin and cyclophosphamide, followed by paclitaxel. Response was defined as downstaging to maximum ypT1a-b/ypN0. The stromal cells, mainly composed of fibroblast and immune cells, were microdissected from fresh frozen tumor samples and gene expression profile was determined using Agilent SurePrint G3 Human Gene Expression microarrays. Expression levels were compared using MeV (MultiExperiment Viewer) software, applying SAM (significance analysis of microarrays). To classify samples according to tumor response, the order of median based on confidence statements (MedOr) was used, and to identify gene sets correlated with the phenotype downstaging, gene set enrichment analysis (GSEA). Nine patients presented disease downstaging. Eleven sequences (FDR 17) were differentially expressed, all of which (except H2AFJ) more expressed in responsive tumors, including PTCHD1 and genes involved in abnormal cytotoxic T cell physiology, TOX, LY75, and SH2D1A. The following four pairs of markers could correctly classify all tumor samples according to response: PTCHD1/PDXDC2P, LOC100506731/NEURL4, SH2D1A/ENST00000478672, and TOX/H2AFJ. Gene sets correlated with tumor downstaging (FDR <0.01) were mainly involved in immune response or lymphocyte activation, including CD47, LCK, NCK1, CD24, CD3E, ZAP70, FOXP3, and CD74, among others. In locally advanced breast cancer, stromal cells may present specific features of immune response that may be associated with chemotherapy response.

Original languageEnglish
Article number1566
Number of pages16
JournalCells
Volume8
Issue number12
DOIs
Publication statusPublished - Dec 2019

Cite this

Hirata Katayama, M. L., Costa Vieira, R. A., Andrade, V. P., Roela, R. A., Cernaglia Aureliano Lima, L. G., Kerr, L. M., ... Azevedo Koike Folgueira, M. A. (2019). Stromal Cell Signature Associated with Response to Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer. Cells, 8(12), [1566]. https://doi.org/10.3390/cells8121566